Frontlight ResearchEarly access
Not yet taking people in FrancePhase 2
Long-term safety of PTI5803 added to treatment for seizures from focal cortical dysplasia
Tests long-term safety of PTI5803 in teens and adults with drug-resistant focal epilepsy.
Key facts
- Who runs it
- PannTheraPi
- Where
- Bron, Marseille, Paris, and Tain-L'hermitage, FranceSee the 4 sites
- Trial code
- Registry title
- A Multicenter, Open-Label, Long-Term, Safety and Tolerability Extension Study of PTI5803 as adjunctive therapy in patients ≥ 14 years of age with drug-resistant seizures associated to focal cortical dysplasia.
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 15 people, planned
- Starts
- 1 Apr 2027
- Expected to end
- 30 Apr 2030
- Type of study
- Interventional
- Record updated
- 31 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with drug-resistant seizures linked to focal cortical dysplasia who finished the earlier study A_CL_002. They would take PTI5803 as an add-on treatment in a long-term safety study.
- Age
- 14 years or older, up to 64 years.
- Sex
- All sexes can join.
- Disease stage
- Drug-resistant seizures linked to focal cortical dysplasia.
- Earlier treatment
- Must have finished the treatment period of the earlier study A_CL_002, taken at least 80% of the planned doses, and not stopped the study drug.
Main reasons for not taking part
- Met any of the withdrawal criteria of the earlier study A_CL_002
- Any medical condition or personal circumstance that the investigator thinks makes taking part too risky or stops following the protocol
- Pregnant, breastfeeding, or planning to become pregnant during the study
- Planning to join a trial with a different investigational drug or use an experimental device
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Written informed consent is signed by the subject and/or their legal representative(s) in accordance with the protocol, ICH GCP and applicable local regulations
- Subject has successfully completed the Treatment Period of the primary study (A_CL_002) and who maintained at least 80% compliance with the protocol defined dose-regimen (diary completion and IMP administration compliance ≥80%) and did not terminate study drug
- Subject has no important protocol deviations (e.g., that may impact patient safety, or data integrity) that in the opinion of the sponsor should preclude participation in this study and has no ongoing adverse events (AEs) that, in the opinion of the investigator, would preclude the patient’s entry into this study
- Subject is expected to experience benefit from their participation, in the opinion of the investigator
- Female subject of childbearing potential must be willing to comply with the contraception requirements as defined in the protocol
- Subject or caregiver is willing and able to comply with all study procedures including seizure diary completion
Who cannot take part
- Subject planning to enter a clinical trial with a different investigational drug or plan to use any experimental device for treatment of epilepsy or any other medical condition
- Any medical condition, personal circumstance that in the opinion of the investigator exposes the patient to unacceptable risk by participating in the extension study or prevents adherence to the protocol
- Subject who met any of the withdrawal criteria of the primary study (A_CL_002)
- Female subject who are pregnant, breastfeeding, or planning to become pregnant during the study
Where in France
- Hospices Civils de Lyon - Hôpital Pierre WertheimerBron, FranceNot yet recruiting
- Assistance Publique Des Hopitaux de MarseilleMarseille, FranceNot yet recruiting
- Fondation A. de RothschildParis, FranceNot yet recruiting
- Ets Medical De La TeppeTain-L'hermitage, FranceNot yet recruiting
About the trial
What the trial wants to find out
To assess the long-term safety and tolerability of PTI5803 in patients with drug-resistant seizures associated to FCD.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- A Multicenter, Open-Label, Long-Term, Safety and Tolerability Extension Study of PTI5803 as adjunctive therapy in patients ≥ 14 years of age with drug-resistant seizures associated to focal cortical dysplasia.
- Plain-language title
- Long-term safety of PTI5803 added to treatment for seizures from focal cortical dysplasiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 31 July 2026